Latest Research Development News

Memphasys Limited has disclosed a $1.118 million liability linked to its FY24 R&D tax rebate following an ASX inquiry, while confirming compliance with continuous disclosure rules and ongoing engagement with the ATO for a private ruling.

Dotz Nano Limited has raised an additional A$460,000 through unsecured loans, bringing total funding under this facility to A$1.2 million to support working capital needs.

Micro-X Ltd has received a $5.08 million R&D tax incentive rebate for FY25, with an additional $0.31 million pending approval, reinforcing its innovation-driven growth in medical imaging technology.

Bass Oil Limited reported a 20% increase in August sales revenue alongside a 3.5% rise in daily production, while progressing regulatory approval for its strategic Vanessa gas field acquisition.

Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

Metal Powder Works Limited reported a 15% revenue decline and a 224% surge in net loss for FY2025, driven by acquisition costs and a pivot towards long-term contracts.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

Asset Vision Co Limited reported a 22.9% increase in revenue to $5.03 million for FY2025, alongside a widening net loss of $385,797. The company’s Annual Recurring Revenue surged 28%, supported by new contracts and product innovation.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.